Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)

Last updated: August 16, 2021
Sponsor: Nanfang Hospital of Southern Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Vascular Diseases

Stress

Williams Syndrome

Treatment

N/A

Clinical Study ID

NCT03713606
Pan-CHESS1802
  • Ages 18-75
  • All Genders

Study Summary

This is a prospective, multi-center diagnostic trial conducted at 6 liver centers in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and hepatic venous pressure gradient in cirrhosis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • age 18-75 years;
  • confirmed cirrhosis based on histologic examination of liver or combined physical,laboratory, and radiologic findings, including a nodular surface, a coarse texture,and an enlarged caudate lobe of the liver.

Exclusion

Exclusion Criteria:

  • prior drug therapy (e.g. β-blocker, vasopressin) within two weeks
  • prior surgeries (e.g. TIPS, partial splenic embolization/ devascularization,splenectomy, liver transplantation)
  • non-sinusoidal portal hypertension & HCC inability to adhere to study procedures
  • pregnancy or unknown pregnancy status
  • no informed consent

Study Design

Total Participants: 75
Study Start date:
September 30, 2018
Estimated Completion Date:
June 01, 2022

Study Description

Hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure, of which the measurement is invasive and therefore not suitable for routine clinical practice. The detection of serum biomarkers is potential for noninvasive diagnosis of portal hypertension in cirrhosis. However, many are still in the exploratory phases of testing and are not yet ready to enter clinical practice. This study prospectively enrolled participants in 6 liver centers (Beijing YouAn Hospital, Shandong Provincial Hospital, Beijing Shijitan Hospital, Beijing Friendship Hospital, Xingtai People's Hospital, and 302 Hospital of PLA) in China designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and HVPG in cirrhosis.

Connect with a study center

  • 302 Hospital of PLA

    Beijing,
    China

    Active - Recruiting

  • Beijing Friendship Hospital

    Beijing,
    China

    Active - Recruiting

  • Beijing Shijitan Hospital

    Beijing,
    China

    Active - Recruiting

  • Beijing YouAn Hospital

    Beijing,
    China

    Active - Recruiting

  • Shandong Provincial Hospital

    Jinan,
    China

    Active - Recruiting

  • Xingtai People's Hospital

    Xingtai,
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.